Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME of [14C] Fruquintinib in Healthy Male Volunteers
NCT02689752Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Total radioactivity on blood, urine and faeces at 14 days. Started Jul 2016; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02689752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689752.